Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 4
2005 1
2008 1
2014 1
2016 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Treatment for osteoporosis in people with beta-thalassaemia.
Bhardwaj A, Swe KMM, Sinha NK. Bhardwaj A, et al. Cochrane Database Syst Rev. 2023 May 9;5(5):CD010429. doi: 10.1002/14651858.CD010429.pub3. Cochrane Database Syst Rev. 2023. PMID: 37159055 Review.
BACKGROUND: Osteoporosis is characterized by low bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility. ...Denosumab, a fully human monoclonal antibody, inhibits bone resorption and increases bone min …
BACKGROUND: Osteoporosis is characterized by low bone mass and micro-architectural deterioration of bone tissue leading to inc …
Efficacy of alendronate in adults with cystic fibrosis with low bone density.
Aris RM, Lester GE, Caminiti M, Blackwood AD, Hensler M, Lark RK, Hecker TM, Renner JB, Guillen U, Brown SA, Neuringer IP, Chalermskulrat W, Ontjes DA. Aris RM, et al. Am J Respir Crit Care Med. 2004 Jan 1;169(1):77-82. doi: 10.1164/rccm.200307-1049OC. Epub 2003 Oct 16. Am J Respir Crit Care Med. 2004. PMID: 14563654 Clinical Trial.
As adults with cystic fibrosis (CF) have enjoyed incremental increases in longevity over the last few decades, they have also been suffering from low bone density and its clinical manifestations, fractures and kyphosis. ...Alendronate was more e …
As adults with cystic fibrosis (CF) have enjoyed incremental increases in longevity over the last few decades, they have also …
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Jeffery TC, Chang AB, Conwell LS. Jeffery TC, et al. Cochrane Database Syst Rev. 2023 Jan 10;1(1):CD002010. doi: 10.1002/14651858.CD002010.pub5. Cochrane Database Syst Rev. 2023. PMID: 36625789 Free PMC article. Review.
BACKGROUND: Osteoporosis is a disorder of bone mineralisation occurring in about one third of adults with cystic fibrosis. ...OBJECTIVES: To assess the effects of bisphosphonates on the frequency of fractures, bone mineral density, quality of li …
BACKGROUND: Osteoporosis is a disorder of bone mineralisation occurring in about one third of adults with cystic fibrosis …
Oral antiresorptive therapy.
Pande I, Hosking DJ. Pande I, et al. Curr Rheumatol Rep. 2005 Mar;7(1):71-7. doi: 10.1007/s11926-005-0012-0. Curr Rheumatol Rep. 2005. PMID: 15760584 Review.
Increasingly these agents are being used to reduce bone loss in other diseases associated with high risk for osteoporosis such as organ transplantation and cystic fibrosis. ...The major problem that remains is the lack of direct comparison between the …
Increasingly these agents are being used to reduce bone loss in other diseases associated with high risk for osteoporosis such …
Treatment for osteoporosis in people with ß-thalassaemia.
Bhardwaj A, Swe KM, Sinha NK, Osunkwo I. Bhardwaj A, et al. Cochrane Database Syst Rev. 2016 Mar 10;3:CD010429. doi: 10.1002/14651858.CD010429.pub2. Cochrane Database Syst Rev. 2016. PMID: 26964506 Updated. Review.
BACKGROUND: Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture. ...OBJECTIVES: To review the eviden …
BACKGROUND: Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bo …
Management of osteoporosis in adults with cystic fibrosis.
Hecker TM, Aris RM. Hecker TM, et al. Drugs. 2004;64(2):133-47. doi: 10.2165/00003495-200464020-00002. Drugs. 2004. PMID: 14717616 Review.
Cystic fibrosis (CF) is the most common genetic disease that causes respiratory failure within the Caucasian population. ...Bisphosphonates, including pamidronic acid, etidronic acid and alendronic acid, reduce bone resorption by inhibiting the recruit …
Cystic fibrosis (CF) is the most common genetic disease that causes respiratory failure within the Caucasian population. ...Bi …
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).
Papaioannou A, Kennedy CC, Freitag A, Ioannidis G, O'Neill J, Webber C, Pui M, Berthiaume Y, Rabin HR, Paterson N, Jeanneret A, Matouk E, Villeneuve J, Nixon M, Adachi JD. Papaioannou A, et al. Chest. 2008 Oct;134(4):794-800. doi: 10.1378/chest.08-0608. Epub 2008 Jul 18. Chest. 2008. PMID: 18641106 Free PMC article. Clinical Trial.
BACKGROUND: Patients with cystic fibrosis (CF) are at risk for early bone loss, and demonstrate increased risks for vertebral fractures and kyphosis. A multicenter, randomized, controlled trial was conducted to assess the efficacy, tolerability, and sa …
BACKGROUND: Patients with cystic fibrosis (CF) are at risk for early bone loss, and demonstrate increased risks for ver …
A review of osteoporosis management in younger premenopausal women.
McLendon AN, Woodis CB. McLendon AN, et al. Womens Health (Lond). 2014 Jan;10(1):59-77. doi: 10.2217/whe.13.73. Womens Health (Lond). 2014. PMID: 24328599 Free article. Review.
Limited data were found to support the treatment of osteoporosis in women with idiopathic osteoporosis or cystic fibrosis, or after kidney transplant. The evidence for treatment of osteoporosis in premenopausal women is not nearly as robust as that for postmenopausa …
Limited data were found to support the treatment of osteoporosis in women with idiopathic osteoporosis or cystic fibrosis, or …
Recognizing and treating glucocorticoid-induced osteoporosis in patients with pulmonary diseases.
Gluck O, Colice G. Gluck O, et al. Chest. 2004 May;125(5):1859-76. doi: 10.1378/chest.125.5.1859. Chest. 2004. PMID: 15136401 Review.
Glucocorticoids are frequently used to treat patients with pulmonary diseases, but continuous long-term use of glucocorticoids may lead to significant bone loss and an increased risk of fragility fractures. Patients with certain lung diseases, regardle …
Glucocorticoids are frequently used to treat patients with pulmonary diseases, but continuous long-term use of glucocorticoids may le …
Oral antiresorptive therapy.
Pande I, Hosking DJ. Pande I, et al. Curr Osteoporos Rep. 2004 Dec;2(4):116-22. doi: 10.1007/BF02686924. Curr Osteoporos Rep. 2004. PMID: 16036092 Review.
Increasingly these agents are being used to reduce bone loss in other diseases associated with high risk for osteoporosis such as organ transplantation and cystic fibrosis. ...The major problem that remains is the lack of direct comparison between the …
Increasingly these agents are being used to reduce bone loss in other diseases associated with high risk for osteoporosis such …